non-steroidal anti-inflammatory drugs for COVID-19 - living meta-analysis of clinical studies

meta|evidence COVID-19

Living systematic review and meta-analysis

vs. potential COVID-19 treatments
vs. adjuvant therapies
vs. paracetamol
vs. control

All
COVID 19 hospitalized
COVID 19 all comers
COVID-19 mild to moderate
COVID-19 severe or critically
COVID 19 outpatients
COVID-19 (hospitalized or not)
COVID-19 prophylaxis (children)
COVID-19 prophylaxis (excluding children)
infections other than COVID-19
Long COVID-19
preventing respiratory virus transmission
root
secondary prevention

Studies
Mapping
Meta-analysis
Excluded 0

table network network 2

display ongoing demontrated benefit only

popup

Wenxin, 2020 ChiCTR2000031630.

Celecoxib vs. control

COVID 19 hospitalized

Bruce, 2020

non-steroidal anti-inflammatory drugs vs. control

COVID 19 hospitalized

Imam, 2020

non-steroidal anti-inflammatory drugs vs. control

COVID 19 hospitalized

Drake, 2021

non-steroidal anti-inflammatory drugs vs. control

COVID 19 hospitalized

Jeong, 2020

non-steroidal anti-inflammatory drugs vs. control

COVID 19 hospitalized

Ravichandran, 2020

Indomethacin vs. paracetamol

COVID-19 mild to moderate

Ravichandran, 2021 CTRI/2021/05/033544

Indomethacin vs. paracetamol

COVID-19 mild to moderate

Guzman-Esquivel, 2022

non-steroidal anti-inflammatory drugs vs. placebo

COVID-19 mild to moderate

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -

Extraction panel open

An extraction panel is open